GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

I’m trying to lose the 18 pounds I have gained since the pandemic. It has been hard enough that I’m wondering about Ozempic.

Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

The surge of online weight-loss drug providers is unexpectedly fueling demand for a much older, once-stigmatized treatment: ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...